The accompanying notes are an integral part of these unaudited consolidated financial statements.
The accompanying notes are an integral part of these unaudited consolidated financial statements.
The accompanying notes are an integral part of these unaudited consolidated financial statements.
The accompanying notes are an integral part of these unaudited consolidated financial statements.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited, in millions, except share and per share data)
1. Basis of presentation
Throughout this Quarterly Report on Form 10-Q, unless the context states otherwise, the words “we,” “us,” “our” and “Analogic” refer to Analogic Corporation and all of its subsidiaries taken as a whole, and “our board of directors” refers to the board of directors of Analogic Corporation.
Our unaudited consolidated financial statements presented herein have been prepared pursuant to the rules of the United States Securities and Exchange Commission, or SEC, for quarterly reports on Form 10-Q. Preparing financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. We report our financial condition and results of operations on a fiscal year basis ending on July 31st of each year. The three months ended October 31, 2017 and 2016 represent the first quarters of fiscal years 2018 and 2017, respectively.
In our opinion, the accompanying unaudited consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary for a fair statement of the results for all interim periods presented. The results of operations for the three months ended October 31, 2017 are not necessarily indicative of the operating results for the full year. These statements should be read in conjunction with the consolidated financial statements and notes thereto for the fiscal year ended July 31, 2017, or fiscal year 2017, included in our Annual Report on Form 10-K as filed with the SEC on September 26, 2017. The year-end balance sheet data was derived from audited financial statements, but does not include all disclosures required by generally accepted accounting principles, or GAAP, in the United States of America.
Consolidation
The unaudited consolidated financial statements presented herein include our accounts and those of our subsidiaries, all of which are wholly owned. All intercompany accounts and transactions have been eliminated in consolidation.
In determining whether we are the primary beneficiary of an entity and therefore required to consolidate, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We have not been required to consolidate the activity of any entity due to these considerations.
2. Recent accounting pronouncements
Accounting pronouncements issued and recently adopted
Improvements to employee share-based payment accounting
In March 2016, the FASB issued ASU No. 2016-09, “
Improvements to Employee Share-Based Payment Accounting
,” which amends ASC 718, “
Stock Based Compensation
.” The amendments require that all excess tax benefits be recorded as an income tax benefit or expense in the income statement and be classified as an operating activity in the statement of cash flows. Entities may also elect to estimate the amount of forfeitures or recognize them as they occur. The amendments are effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. The standard was effective for us in the first quarter of fiscal 2018 ending July 31, 2018. Effective August 1, 2017, we adopted ASU 2016-09.
We elected to account for forfeitures as they occur and therefore, share-based compensation expense for the first quarter of fiscal 2018 ended October 31, 2017 has been calculated based on actual forfeitures in our
Consolidated Statements of Operations
, rather than our previous approach which was net of estimated forfeitures. Subsequent to adoption, excess tax benefits or deficiencies from share-based payment awards are recorded in the
Consolidated Statements of Operations
as a component of the Provision for income taxes, whereas these previously were recognized in Capital in excess of par value (APIC) in the Consolidated Balance Sheets. Additionally, subsequent to
adoption, we classified any excess tax benefits or deficiencies as an operating activity
in the Consolidated Statement of Cash Flows on a prospective basis
, while we previously classified excess tax benefits or deficiencies within financing activities within the Consolidated Statement of Cash Flows. The adoption of ASU 2016-09 resulted in a cumulative adjustment of a $0.8 million increase to Retained earnings as of August 1, 2017 on a modified retrospective basis.
7
Accounting pronouncements issued and not yet effective
Scope of Modification Accounting
In May 2017, the FASB
issued ASU No. 2017-09, “
Compensation – Stock Compensation (Topic 718)”.
The standard provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. ASU 2017-09 is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, and should be applied prospectively to an award modified on or after the adoption date. Early adoption is permitted.
The standard will be effective for us in the first quarter of our fiscal year ending July
31, 2019.
We are currently evaluating the impact of the adoption of this update on our consolidated financial statements.
Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost
In March 2017, the FASB issued ASU No. 2017-07, “
Compensation — Retirement Benefits (Topic 715)”
. The standard improves the presentation of net periodic pension cost and net periodic postretirement benefit cost by requiring that an employer that offers to its employees defined benefit pension or other postretirement benefit plans report the service cost component in the same line item or items as other compensation costs arising from services rendered by the pertinent employees during the period. The other components of net benefit cost are required to be presented in the income statement separately from the service cost component and outside a subtotal of income from operations, if one is presented. The standard is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted.
The standard will be effective for us in the fiscal year beginning August 1, 2018.
We are currently evaluating the impact of the adoption of this update on our consolidated financial statements.
Clarifying the Definition of a Business
In January 2017, the FASB issued ASU No. 2017-01,
“Business Combinations (Topic 805):
Clarifying the Definition of a Business.”
The amendments provide the requirements needed for a set of transferred assets and activities to be a business and establish a practical way to determine when a set of transferred assets and activities is not a business. To be considered a business, an acquisition would have to include an input and a substantive process that together significantly contribute to the ability to create outputs. An output is the result of inputs and substantive processes that provide goods or services to customers, other revenue, or investment income, such as dividends and interest. The amendments narrow the definition of outputs and align it with how outputs are described in Topic 606 “Revenue from Contracts with Customers”. The amendments are effective for annual periods beginning after December 15, 2017, including interim periods within those periods. Early adoption is permitted. The standard will be effective for us in the fiscal year beginning August 1, 2018. We are currently evaluating the impact of the adoption of this update on our consolidated financial statements.
Intra-Entity Transfers of Assets Other than Inventory
In October 2016, the FASB issued ASU No. 2016-16, “
Income Taxes (Topic 740)
”. The standard requires the recognition of the income tax consequences of an intra-entity transfer of an asset, other than inventory, when the transfer occurs.
Two common examples of assets included in the scope of this amendment are intellectual property and property, plant, and equipment. The amendments are effective for annual reporting periods beginning after December 15, 2017, including interim reporting periods within those annual reporting periods.
Early adoption is permitted. The standard will be effective for us in the fiscal year beginning August 1, 2018. We are currently evaluating the impact of the adoption of this update on our consolidated financial statements.
Classification of Certain Cash Receipts and Cash Payments
In August 2016, the FASB issued ASU No. 2016-15, “
Statement of Cash Flows (Topic 230).”
The amendments provide guidance on the eight specific cash flow statement presentation and classification issues as follows: (1) debt prepayment or debt extinguishment costs; (2) settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; (3) contingent consideration payments made after a business combination; (4) proceeds from the settlement of insurance claims; (5) proceeds from the settlement of corporate-owned life insurance policies, including bank-owned life insurance policies; (6) distributions received from equity method investees; (7) beneficial interests in securitization transactions; and (8) separately identifiable cash flows and application of the predominance principle. The amendments are effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The standard will be effective for us in the first quarter of our fiscal year ending July
31, 2019. We are currently evaluating the impact of the adoption of this update on our consolidated financial statements.
8
Measurement of Credit Losses on Financial Instruments
In June 2016, the FASB issued ASU No. 2016-13, “
Financial Instruments – Credit Losses (Topic 326)
” The amendment modifies the measurement of expected credit losses of certain financial instruments.
Credit losses relating to available-for-sale debt securities should be recorded through an allowance for credit losses. Available-for-sale accounting recognizes that value may be realized either through collection of contractual cash flows or through sale of the security. Therefore, the amendments limit the amount of the allowance for credit losses to the amount by which fair value is below amortized cost because the classification as available for sale is premised on an investment strategy that recognizes that the investment could be sold at fair value, if cash collection would result in the realization of an amount less than fair value. The allowance for credit losses for purchased available-for-sale securities with a more-than-insignificant amount of credit deterioration since origination is determined in a similar manner to other available-for-sale debt securities; however, the initial allowance for credit losses is added to the purchase price rather than reported as a credit loss expense. Only subsequent changes in the allowance for credit losses are recorded in credit loss expense. Interest income should be recognized based on the effective interest rate, excluding the discount embedded in the purchase price that is attributable to the acquirer’s assessment of credit losses at acquisition. The amendments are effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years.
The standard will be effective for us in the fiscal year beginning after August 01, 2020.
We are currently evaluating the impact of the adoption of this update on our consolidated financial statements.
Leases
In February 2016, the FASB issued ASU No. 2016-02, “
Leases (Topic 842)
”. The standard requires lessees to recognize assets and liabilities for most leases on the balance sheet. For income statement purposes, the standard requires leases to be classified as either operating or finance. The standard is effective for annual and interim periods beginning after December 15, 2018. Early adoption is permitted. The standard will be effective for us in the first quarter of our fiscal year ending July 31, 2020. Adoption requires application of the new guidance for all periods presented. We are currently evaluating the impact of the adoption of this standard on our consolidated financial statements.
Revenue from contracts with customers
In May 2014, the FASB issued ASU No. 2014-09, “
Revenue from Contracts with Customers (Topic 606)
”. This update affects any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets. This update will supersede existing revenue recognition requirements and most industry-specific guidance. This update also supersedes some cost guidance, including revenue recognition guidance for construction-type and production-type contracts. The update’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under today’s guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. This update should be applied either on a retrospective or modified retrospective basis. This update was originally effective for us in the first quarter of our fiscal year ending July 31, 2018. Early adoption was not permitted. In August 2015, the FASB approved a one year delay of the effective date of the new revenue standard for public entities. Therefore, this update would be effective for us in the first quarter of our fiscal year ending July 31, 2019. The standard permits entities to early adopt, but only as of the original effective date (i.e. one year earlier). We are expected to adopt the new standard in the first quarter of our fiscal year 2019 effective August 01, 2018. We are still in the early stage of assessing the adoption method and analyzing the impact of the adoption of this update on our consolidated financial statements. We established a project plan and an implementation team. Preliminary scoping and testing have been completed, with detail contract review underway. We are unable to quantify the impact at this time. The implementation team continues to apprise both management and the Audit Committee of project status on a recurring basis.
3. Accounts receivable, net
Our accounts receivable arise primarily from products sold and services provided in North America, Europe and Asia. The balance in accounts receivable represents the amount due from our domestic and foreign original equipment manufacturers, or OEM, customers, distributors and end users. We perform ongoing credit evaluations of our customers’ financial condition and continuously monitor collections and payments from our customers and maintain a provision for estimated credit losses based upon specific customer collection issues that have been identified. We accrue reserves against trade receivables for estimated losses that may result from a customer’s inability to pay. Amounts determined to be uncollectible are charged or written off against the reserve. To date, our historical bad debts charged against the reserve have been minimal.
9
Our top ten customers combined accounted for approximately
53%
and
64%
of our total net revenue for each of the three months ended October 31, 2017 and 2016, respectively. Set forth in the table below are customers that individually accounted for 10% or
more of our net revenue.
|
|
Three Months Ended
|
|
|
|
October 31,
|
|
|
|
2017
|
|
|
2016
|
|
Koninklijke Philips Electronics N.V., or Philips
|
|
|
12
|
%
|
|
|
13
|
%
|
Siemens AG
|
|
|
12
|
%
|
|
|
13
|
%
|
L-3 Communications Corporation, or L-3
|
|
*
|
|
|
|
10
|
%
|
Note (*): Total net revenue was less than 10% in this period.
The following table summarizes our customers with net accounts receivable balances greater than or equal to 10% of our total net accounts receivable balance:
|
|
As of
|
|
|
As of
|
|
|
|
October 31,
|
|
|
July 31,
|
|
|
|
2017
|
|
|
2017
|
|
Philips
|
|
|
15
|
%
|
|
|
14
|
%
|
Smiths Detection
|
|
|
10
|
%
|
|
*
|
|
GE
|
|
*
|
|
|
|
11
|
%
|
Note (*): Total net accounts receivable balance was less than 10% in this period.
4. Inventory
The components of inventory, net of allowance for obsolete, unmarketable or slow-moving inventories, are summarized as follows:
|
|
As of
|
|
|
As of
|
|
|
|
October 31,
|
|
|
July 31,
|
|
(in millions)
|
|
2017
|
|
|
2017
|
|
Raw materials
|
|
$
|
60.1
|
|
|
$
|
62.8
|
|
Work in process
|
|
|
43.8
|
|
|
|
41.8
|
|
Finished goods
|
|
|
27.4
|
|
|
|
26.0
|
|
Total inventory
|
|
$
|
131.3
|
|
|
$
|
130.6
|
|
5. Intangible assets and goodwill
Intangible assets
Intangible assets include the value assigned to intellectual property and other technology, patents, customer contracts and relationships, and trade names. The estimated useful lives for all of these intangible assets, excluding a trade name determined to have an indefinite life, range between 1 to 14 years. Indefinite-lived intangible assets consist of trade names acquired in business combinations. The carrying values of our indefinite-lived intangible assets were $7.6 million at both the three months ended October 31, 2017 and July 31, 2017.
Finite-lived intangible assets are summarized as follows:
|
|
|
|
As of October 31, 2017
|
|
|
As of July 31, 2017
|
|
(in millions)
|
|
Weighted
Average
Amortization
Period
|
|
Cost
|
|
|
Accumulated
Amortization/
Write-Offs
|
|
|
Net
|
|
|
Cost
|
|
|
Accumulated
Amortization
|
|
|
Net
|
|
Developed technologies
|
|
10 years
|
|
$
|
17.7
|
|
|
$
|
14.8
|
|
|
$
|
2.9
|
|
|
$
|
17.7
|
|
|
$
|
14.4
|
|
|
$
|
3.3
|
|
Customer relationships
|
|
13 years
|
|
|
43.7
|
|
|
|
29.6
|
|
|
|
14.1
|
|
|
|
43.7
|
|
|
|
28.7
|
|
|
|
15.0
|
|
Trade names
|
|
3 years
|
|
|
0.9
|
|
|
|
0.9
|
|
|
|
-
|
|
|
|
0.9
|
|
|
|
0.9
|
|
|
|
-
|
|
Total finite-lived intangible assets
|
|
|
|
$
|
62.3
|
|
|
$
|
45.3
|
|
|
$
|
17.0
|
|
|
$
|
62.3
|
|
|
$
|
44.0
|
|
|
$
|
18.3
|
|
10
Amortization expense related to acquired intangible assets was $1.3 million and $2.0 million for each of the three months ended Octobe
r 31, 2017 and 2016, respectively.
Goodwill
We had goodwill balances of $2.3 million at both October 31, 2017 and July 31, 2017. We review periodically
or more frequently if indicators are present or changes in circumstances suggest that it is more likely than not that impairment may exist
and we perform a formal goodwill impairment test in the second quarter of each fiscal year.
The goodwill balance by reportable segments and reporting unit at both the three months ended October 31, 2017 and July 31, 2017 are as follows:
|
|
Medical Imaging
|
|
|
Ultrasound
|
|
|
Security and Detection
|
|
|
|
|
|
(in millions)
|
|
(Medical Imaging
Reporting Unit)
|
|
|
(Ultrasound
Reporting Unit)
|
|
|
(Oncura
Reporting Unit)
|
|
|
(Security and
Detection
Reporting Unit)
|
|
|
Total
Goodwill
|
|
Balance as of July 31, 2017
|
|
$
|
1.8
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
0.5
|
|
|
$
|
2.3
|
|
Balance as of October 31, 2017
|
|
$
|
1.8
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
0.5
|
|
|
$
|
2.3
|
|
The following is a rollforward of accumulated goodwill impairment losses by reportable segment and reporting unit:
|
|
Medical Imaging
|
|
|
Ultrasound
|
|
|
Security and Detection
|
|
|
|
|
|
(in millions)
|
|
(Medical Imaging
Reporting Unit)
|
|
|
(Ultrasound
Reporting Unit)
|
|
|
(Oncura
Reporting Unit)
|
|
|
(Security and
Detection
Reporting Unit)
|
|
|
Total
|
|
Accumulated impairment losses as
of July 31, 2017
|
|
$
|
-
|
|
|
$
|
(55.2
|
)
|
|
$
|
(16.4
|
)
|
|
$
|
-
|
|
|
$
|
(71.6
|
)
|
Accumulated impairment losses
as of October 31, 2017
|
|
$
|
-
|
|
|
$
|
(55.2
|
)
|
|
$
|
(16.4
|
)
|
|
$
|
-
|
|
|
$
|
(71.6
|
)
|
6. Fair value measurements
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. We use a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:
|
•
|
Level 1 – Quoted prices in active markets for identical assets or liabilities.
|
|
•
|
Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
|
|
•
|
Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
|
11
The following tables provide the assets and liabilities carried at fair value and measured on a recurring basis at October 31, 2017 an
d July 31, 2017:
|
|
Fair Value Measurement as of October 31, 2017
|
|
(in millions)
|
|
Adjusted
Cost
|
|
|
Unrealized
Gains
|
|
|
Unrealized
Losses
|
|
|
Fair
Value
|
|
|
Cash and
Cash
Equivalents
|
|
|
Marketable
Securities
|
|
Cash
|
|
$
|
43.4
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
43.4
|
|
|
$
|
43.4
|
|
|
$
|
-
|
|
Level 1:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Money market funds
|
|
|
32.4
|
|
|
|
-
|
|
|
|
-
|
|
|
|
32.4
|
|
|
|
32.4
|
|
|
|
-
|
|
Subtotal
|
|
$
|
75.8
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
75.8
|
|
|
$
|
75.8
|
|
|
$
|
-
|
|
Level 2:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S. agency securities
|
|
$
|
4.0
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
4.0
|
|
|
$
|
-
|
|
|
$
|
4.0
|
|
Non-U.S. government securities
|
|
|
10.5
|
|
|
|
-
|
|
|
|
-
|
|
|
|
10.5
|
|
|
|
-
|
|
|
|
10.5
|
|
Commercial paper
|
|
|
27.7
|
|
|
|
-
|
|
|
|
-
|
|
|
|
27.7
|
|
|
|
21.0
|
|
|
|
6.7
|
|
Corporate securities
|
|
|
40.4
|
|
|
|
-
|
|
|
|
(0.03
|
)
|
|
|
40.4
|
|
|
|
-
|
|
|
|
40.4
|
|
Asset-backed securities
|
|
|
24.5
|
|
|
|
-
|
|
|
|
(0.02
|
)
|
|
|
24.5
|
|
|
|
-
|
|
|
|
24.5
|
|
Subtotal
|
|
$
|
107.1
|
|
|
$
|
-
|
|
|
$
|
(0.05
|
)
|
|
$
|
107.1
|
|
|
$
|
21.0
|
|
|
$
|
86.1
|
|
Total
|
|
$
|
182.9
|
|
|
$
|
-
|
|
|
$
|
(0.05
|
)
|
|
$
|
182.9
|
|
|
$
|
96.8
|
|
|
$
|
86.1
|
|
|
|
Fair Value Measurement as of July 31, 2017
|
|
(in millions)
|
|
Adjusted
Cost
|
|
|
Unrealized
Gains
|
|
|
Unrealized
Losses
|
|
|
Fair
Value
|
|
|
Cash and
Cash
Equivalents
|
|
|
Marketable
Securities
|
|
Cash
|
|
$
|
46.7
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
46.7
|
|
|
$
|
46.7
|
|
|
$
|
-
|
|
Level 1:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Money market funds
|
|
|
38.4
|
|
|
|
-
|
|
|
|
-
|
|
|
|
38.4
|
|
|
|
38.4
|
|
|
|
-
|
|
Subtotal
|
|
$
|
85.1
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
85.1
|
|
|
$
|
85.1
|
|
|
$
|
-
|
|
Level 2:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S. Treasury securities
|
|
$
|
10.0
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
10.0
|
|
|
$
|
10.0
|
|
|
$
|
-
|
|
U.S. agency securities
|
|
|
7.0
|
|
|
|
-
|
|
|
|
-
|
|
|
|
7.0
|
|
|
|
7.0
|
|
|
|
-
|
|
Non-U.S. government securities
|
|
|
3.9
|
|
|
|
-
|
|
|
|
-
|
|
|
|
3.9
|
|
|
|
-
|
|
|
|
3.9
|
|
Commercial paper
|
|
|
30.1
|
|
|
|
-
|
|
|
|
-
|
|
|
|
30.1
|
|
|
|
27.2
|
|
|
|
2.9
|
|
Corporate securities
|
|
|
28.0
|
|
|
|
-
|
|
|
|
(0.01
|
)
|
|
|
28.0
|
|
|
|
-
|
|
|
|
28.0
|
|
Asset-backed securities
|
|
|
10.2
|
|
|
|
-
|
|
|
|
-
|
|
|
|
10.2
|
|
|
|
-
|
|
|
|
10.2
|
|
Subtotal
|
|
$
|
89.2
|
|
|
$
|
-
|
|
|
$
|
(0.01
|
)
|
|
$
|
89.2
|
|
|
$
|
44.2
|
|
|
$
|
45.0
|
|
Total
|
|
$
|
174.3
|
|
|
$
|
-
|
|
|
$
|
(0.01
|
)
|
|
$
|
174.3
|
|
|
$
|
129.3
|
|
|
$
|
45.0
|
|
Plan assets for deferred compensation
|
|
As of
|
|
|
As of
|
|
|
|
October 31,
|
|
|
July 31,
|
|
(in millions)
|
|
2017
|
|
|
2017
|
|
Level 1:
|
|
|
|
|
|
|
|
|
Plan assets for deferred compensation
|
|
|
4.8
|
|
|
|
4.7
|
|
Total
|
|
$
|
4.8
|
|
|
$
|
4.7
|
|
Assets held in the deferred compensation plan will be used to pay benefits under our non-qualified deferred compensation plan. The investments primarily consist of mutual funds that are publicly traded on stock exchanges. Accordingly, the fair value of these assets is categorized as Level 1 within the fair value hierarchy.
Foreign currency forward contracts
|
|
As of
|
|
|
As of
|
|
|
|
October 31,
|
|
|
July 31,
|
|
(in millions)
|
|
2017
|
|
|
2017
|
|
Level 2:
|
|
|
|
|
|
|
|
|
Foreign currency forward contracts asset
|
|
|
0.1
|
|
|
|
0.6
|
|
Total
|
|
$
|
0.1
|
|
|
$
|
0.6
|
|
12
The fair value of the liabilities arising from our foreign currency forward contracts is determined by valuation models based on market observable inputs, including forward and spot prices for
currencies. Accordingly, the fair value of these liabilities is categorized as Level 2 within the fair value hierarchy.
7. Derivative instruments
Certain of our foreign operations have revenue and expenses transacted in currencies other than the U.S. dollar. In order to mitigate foreign currency exchange risk, we use forward contracts to lock in exchange rates associated with a portion of our forecasted international expenses.
As of October 31, 2017, we have forward contracts outstanding with notional amounts totaling $11.3 million. These contracts are designated as cash flow hedges, and the unrealized gain of $0.1 million, net of tax, on these contracts are reported in Accumulated other comprehensive income as of October 31, 2017. Assets and liability derivatives designated as hedging instruments are presented in other current assets and other current liabilities, respectively, on our Consolidated Balance Sheets. At October 31, 2017 we had a derivative asset of $0.1 million included in other current assets on our Consolidated Balance Sheet.
As of July 31, 2017, we had forward contracts outstanding with notional amounts totaling $10.9 million. These contracts are designated as cash flow hedges, and the unrealized gain of $0.5 million, net of tax, on these contracts are reported in Accumulated other comprehensive income as of July 31, 2017. At July 31, 2017 we had a derivative asset of $0.6 million included in other current assets on our Consolidated Balance Sheet.
Realized gains and (losses) on the cash flow hedges are recognized in income in the period when the payment of expenses is recognized. During the three months ended October 31, 2017 and 2016, we recorded approximately $0.2 million of realized gain and ($0.1) million of realized loss, respectively, included in our Consolidated Statements of Operations.
8. Common stock repurchases
On May 26, 2016, our board of directors authorized the repurchase of up to $15.0 million of our common stock. Purchases under this repurchase program will be made from time to time depending on market conditions and other factors. The repurchase program has no expiration date. The Board's authorization does not obligate the Company to acquire any particular amount of common stock, and the programs may be suspended or discontinued at any time at the Company's discretion.
During the three months ended October 31, 2017, we repurchased and retired 13,489 shares of common stock under this repurchase program for $1.0 million at an average purchase price of $70.52 per share. The cumulative shares that were repurchased and retired under the program were 61,197 shares of common stock for $4.4 million at an average purchase price of $71.10 per share.
9. Accumulated other comprehensive income
Components of comprehensive (loss) income include net income and certain transactions that have generally been reported in the Consolidated Statements of Changes in Stockholders’ Equity. Other comprehensive (loss) income consists of reported foreign currency translation gains and losses (net of taxes), actuarial gains and losses on pension plan assets (net of taxes), changes in the unrealized value on foreign currency forward contracts (net of taxes), and changes in the unrealized value on available-for-sale securities (net of taxes). Deferred taxes are not provided on cumulative translation adjustments where we expect earnings of a foreign subsidiary to be indefinitely reinvested. The income tax effect of currency translation adjustments related to foreign subsidiaries that are not considered indefinitely reinvested is recorded as a component of deferred taxes with an offset to other comprehensive (loss) income.
The following table summarizes components of Accumulated other comprehensive (loss) income for the three months ended October 31, 2017:
(in millions)
|
|
Unrealized
Losses
on Available For Sale Securities
|
|
|
Unrealized
Gain
on Foreign
Currency
Forward
Contracts
|
|
|
Unrealized
Losses on
Pension Plan
|
|
|
Currency
Translation
Adjustment
|
|
|
Accumulated
Other
Comprehensive
Income
|
|
Balance as of July 31, 2017
|
|
$
|
(0.01
|
)
|
|
$
|
0.5
|
|
|
$
|
(3.5
|
)
|
|
$
|
(2.1
|
)
|
|
$
|
(5.1
|
)
|
Pre-tax change before reclassification to
earnings
|
|
|
(0.1
|
)
|
|
|
-
|
|
|
|
0.1
|
|
|
|
-
|
|
|
|
-
|
|
Amount reclassified to earnings
|
|
|
-
|
|
|
|
(0.5
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
(0.5
|
)
|
Income tax benefit (provision)
|
|
|
-
|
|
|
|
0.1
|
|
|
|
(0.1
|
)
|
|
|
(0.2
|
)
|
|
|
(0.2
|
)
|
Balance as of October 31, 2017
|
|
$
|
(0.1
|
)
|
|
$
|
0.1
|
|
|
$
|
(3.5
|
)
|
|
$
|
(2.3
|
)
|
|
$
|
(5.8
|
)
|
13
The ineffective portion of the unrealized losses on foreign currency forward contracts and unrealized gains or losses on currency translation adjustment are included in other expense, net on our Consolidated Statements of Operations.
10. Share-based compensation
The following table presents share-based compensation expense included in our Consolidated Statements of Operations:
|
|
Three Months Ended
|
|
|
|
October 31,
|
|
(in millions)
|
|
2017
|
|
|
2016
|
|
Cost of product sales
|
|
$
|
0.1
|
|
|
$
|
0.1
|
|
Cost of engineering sales
|
|
|
-
|
|
|
|
-
|
|
Research and product development
|
|
|
0.4
|
|
|
|
0.3
|
|
Selling and marketing
|
|
|
0.2
|
|
|
|
0.4
|
|
General and administrative
|
|
|
1.3
|
|
|
|
0.8
|
|
Total share-based compensation expense before tax
|
|
|
2.0
|
|
|
|
1.6
|
|
Income tax effect
|
|
|
(0.1
|
)
|
|
|
(0.5
|
)
|
Share-based compensation expense included in net income
|
|
$
|
1.9
|
|
|
$
|
1.1
|
|
In the three months ended October 31, 2017, we adopted ASU 2016-09, “
Improvements to Employee Share-Based Payment Accounting,
” which amends ASC 718, “
Stock Based Compensation
.”
We elected to account for forfeitures as they occur and therefore, share-based compensation expense for the three months ended October 31, 2017 has been calculated based on actual forfeitures, rather than our previous approach which was net of estimated forfeitures. The adoption of ASU 2016-09 resulted in a cumulative adjustment of a $0.8 million increase to Retained earnings as of August 1, 2017 on a modified retrospective basis. Share-based compensation expense for the three months ended October 31, 2016 was recorded net of estimated forfeitures, which were based on historical forfeitures and adjusted to reflect changes in facts and circumstances, if any. Please refer to "Note 2. Recent accounting pronouncements in the notes to our Consolidated Financial Statements for detailed adoption information.
Stock options
We estimate the fair value of stock options using the Black-Scholes valuation model. Key input assumptions used to estimate the fair value of stock options include the exercise price of the award, the expected option term, the expected volatility of our stock over the option’s expected term, the risk-free interest rate over the option’s expected term, and our expected annual dividend yield. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by persons who receive equity awards.
No stock options were granted during three months ended October 31, 2017 and October 31, 2016, respectively.
The total intrinsic value of options exercised during the three months ended October 31, 2017 and 2016 was $0.01 million and $0.7 million, respectively.
Restricted stock and restricted stock units
We estimate the fair value of time based restricted stock units, or RSU’s, that vest based on service conditions using the quoted closing price of our common stock on the date of grant. Share-based compensation expense is amortized over each award’s vesting period on a straight-line basis for all awards with service and performance conditions that vest at the end of the performance cycle, while the accelerated method applies to other awards with both service and performance conditions.
For our non-GAAP earnings per share, or EPS, awards, the compensation cost is amortized over the performance period on a straight-line basis, net of forfeitures, because such awards vest only at the end of the performance period. The compensation cost is based on the number of shares that are deemed probable of vesting at the end of the three-year performance cycle. This probability assessment is done each quarter and changes in estimates can result in significant expense fluctuations due to the cumulative catch-up adjustment. We estimate the fair value of the non-GAAP EPS awards using the quoted closing price of our common stock on the date of grant.
For our total shareholder return, or TSR, awards, the compensation cost is amortized over the performance period on a straight-line basis net of forfeitures, because the awards vest only at the end of the measurement period and the probability of actual shares expected to be earned is considered in the grant date valuation. As a result, the expense is not adjusted to reflect the actual shares earned. We estimate the fair value of the TSR awards using the Monte-Carlo simulation model.
14
We granted
22,080
and
28,148
TSR awards and
21,896
and
62,032
non-GAAP EPS awards during the three months ended October 31, 2017 and October 31, 2016, respectively. The fair value of our TSR performance-based awards at the date of grant was estimated using the Monte-Carlo simulation model with the following assumpti
ons:
|
|
Three Months Ended
|
|
|
|
October 31,
|
|
|
|
2017
|
|
|
2016
|
|
Stock price (1)
|
|
$
|
77.15
|
|
|
$
|
90.23
|
|
Expected volatility (2)
|
|
|
26.88
|
%
|
|
|
27.00
|
%
|
Risk-free interest rate (3)
|
|
|
1.48
|
%
|
|
|
0.85
|
%
|
Expected annual dividend yield (4)
|
|
|
0.00
|
%
|
|
|
0.00
|
%
|
Weighted average grant date fair value of time-based
restricted stock awards
|
|
$
|
77.14
|
|
|
$
|
89.39
|
|
Weighted average grant date fair value of performance
based restricted stock awards
|
|
$
|
77.15
|
|
|
$
|
87.05
|
|
(1)
|
The stock price is the closing price of our common stock on the date of grant.
|
(2)
|
The expected volatility for each grant is determined based on the historical volatility for the peer group companies and our common stock over a period equal to the remaining term of the performance period from the date of grant for all awards.
|
(3)
|
The risk-free interest rate is determined based on the yield of zero-coupon U.S. Treasury securities for a period that is commensurate with the performance period.
|
(4)
|
Dividends are considered reinvested when calculating TSR. The dividend yield is therefore considered to be 0%.
|
The total fair value of RSUs that vested during the three months ended October 31, 2017 and 2016 was $3.1 million and $2.6 million, respectively.
As of October 31, 2017, the unrecognized compensation cost, related to unvested stock options and restricted stock was $13.3 million. This cost will be recognized over an estimated weighted average amortization period of 1.8 years and assumes target performance for the non-GAAP EPS awards.
11. Restructuring charges
Fiscal Year 2017 Restructuring Plan
On March 6, 2017, the Company announced the 2017 Restructuring Plan, which primarily focused on the restructuring of the Ultrasound business, designed to improve profitability and provide consistent long term growth. As part of the 2017 Restructuring Plan, the Company consolidated the activities conducted in Vancouver, British Columbia with the existing operations in Copenhagen, Denmark and Peabody, Massachusetts and the Company substantially exited the Vancouver facility at the end fiscal 2017. The Company re-sized its U.S. sales, global marketing as well as general and administration organizations in-line with its objectives within primarily its Ultrasound business, but also its Medical Imaging and Security and Detection businesses. We incurred pre-tax charges of $0.5 million during the three months ended October 31, 2017. These costs consisted of facility exit costs and adjustments to the severance and personnel related costs, which are recognized in our Consolidated Statement of Operations under restructuring. We expect that the 2017 Restructuring Plan will be substantially completed during fiscal year 2018.
Current Period Activity
The following table summarizes accrued restructuring activities for the three months ended October 31, 2017:
|
|
Employee
|
|
|
|
|
|
|
|
|
|
|
|
Severance
|
|
|
Facility
|
|
|
|
|
|
|
|
and
|
|
|
Exit
|
|
|
|
|
|
(in millions)
|
|
Benefits (A)
|
|
|
Costs (A)
|
|
|
Total
|
|
Balance at July 31, 2017
|
|
$
|
2.7
|
|
|
$
|
0.1
|
|
|
$
|
2.8
|
|
Restructuring charge
|
|
|
0.4
|
|
|
|
0.3
|
|
|
|
0.7
|
|
Adjustments
|
|
|
(0.2
|
)
|
|
|
-
|
|
|
|
(0.2
|
)
|
Cash payments
|
|
|
(1.8
|
)
|
|
|
-
|
|
|
|
(1.8
|
)
|
Non-cash adjustments
|
|
|
-
|
|
|
|
(0.1
|
)
|
|
|
(0.1
|
)
|
Balance at October 31, 2017
|
|
$
|
1.1
|
|
|
$
|
0.3
|
|
|
$
|
1.4
|
|
(A)
|
Restructuring charges in fiscal year 2018 relate to the Fiscal Year 2017 Restructuring Plan.
|
15
The following table summarizes accrued restructuring activities for the three months ended October 31, 2016:
|
|
Employee
|
|
|
|
|
|
|
|
Severance
|
|
|
|
|
|
|
|
and
|
|
|
|
|
|
(in millions)
|
|
Benefits (A)
|
|
|
Total
|
|
Balance at July 31, 2016
|
|
$
|
5.2
|
|
|
$
|
5.2
|
|
Adjustments
|
|
|
0.03
|
|
|
|
0.03
|
|
Cash payments
|
|
|
(2.7
|
)
|
|
|
(2.7
|
)
|
Balance at October 31, 2016
|
|
$
|
2.5
|
|
|
$
|
2.5
|
|
(A)
|
Activity during the period
relates to
our fiscal year 2016
restructuring plan, which was completed in the fourth quarter of fiscal year 2017.
|
Restructuring and related charges, including actions associated with acquisitions, by segment are as follows:
|
|
For Three Months Ended
|
|
|
|
October 31,
|
|
(in millions)
|
|
2017
|
|
|
2016
|
|
Medical Imaging
|
|
$
|
0.1
|
|
|
$
|
0.02
|
|
Ultrasound
|
|
|
0.4
|
|
|
|
0.01
|
|
Security and Detection
|
|
|
-
|
|
|
|
-
|
|
Total restructuring and related charges
|
|
$
|
0.5
|
|
|
$
|
0.03
|
|
Accrued restructuring charges are classified on the Consolidated Balance Sheets in the Current Liabilities section.
12. Net income per common share
Basic net income per share is computed using the weighted average number of common shares outstanding during the period. Diluted net income per share is computed using the sum of the weighted average number of common shares outstanding during the period and, if dilutive, the weighted average number of potential shares of common stock, including unvested restricted stock and the assumed exercise of stock options using the treasury stock method.
Basic and diluted net income per share are calculated as follows:
|
|
Three Months Ended
|
|
|
|
October 31,
|
|
(in millions, except per share data and share data in thousands)
|
|
2017
|
|
|
2016
|
|
Net income
|
|
$
|
5.7
|
|
|
$
|
2.5
|
|
Weighted average number of common shares
outstanding-basic
|
|
|
12,473
|
|
|
|
12,419
|
|
Effect of dilutive securities:
|
|
|
|
|
|
|
|
|
Stock options and restricted stock units
|
|
|
126
|
|
|
|
197
|
|
Weighted average number of common shares
outstanding-diluted
|
|
|
12,599
|
|
|
|
12,616
|
|
Basic net income per share
|
|
$
|
0.45
|
|
|
$
|
0.20
|
|
Diluted net income per share
|
|
$
|
0.45
|
|
|
$
|
0.20
|
|
Anti-dilutive shares related to outstanding stock options
and unvested restricted stock (A)
|
|
|
26
|
|
|
|
1
|
|
(A)
|
These shares related to outstanding stock options and unvested restricted stock were not included in our calculations of diluted earnings per share, as the effect of including them would be anti-dilutive.
|
16
13. Income taxes
The following table presents the provision for income taxes and our effective tax rate for the three months ended October 31, 2017 and 2016:
|
|
Three Months Ended
|
|
|
|
October 31,
|
|
(in millions except percentages)
|
|
2017
|
|
|
2016
|
|
Provision for income taxes
|
|
$
|
2.5
|
|
|
$
|
1.0
|
|
Effective tax rate
|
|
|
30
|
%
|
|
|
28
|
%
|
The effective income tax rate on operations is based upon the estimated income for the year, the composition of the income in different countries, and adjustments, if any, in the applicable quarterly periods for the potential tax consequences, benefits, resolutions of tax audits or other tax contingencies.
Our effective tax rate for the three months ended October 31, 2017 is lower than the statutory rate of 35% primarily due to income generated outside the United States in countries with lower tax rates and tax credits in the United States and Canada, offset by certain discrete tax expense. The tax provision for the three months ended October 31, 2017 includes discrete tax expense totaling $0.5 million.
Our effective tax rate for the three months ended October 31, 2016 lower than the statutory rate of 35% primarily due to income generated outside the United States in countries with lower tax rates, tax credits in the United States and Canada, and the manufacturing deduction in the United States. The tax provision for the three months ended October 31, 2016 includes discrete tax benefits totaling less than $0.1 million.
We are subject to U.S. Federal income tax as well as the income tax of multiple state and foreign jurisdictions. As of October 31, 2017, we have concluded all U.S. Federal income tax matters through the year ended July 31, 2013.
We accrue interest and, if applicable, penalties for any uncertain tax positions. This interest and penalty expense is treated as a component of income tax expense. At October 31, 2017 and July 31, 2017, we had approximately $0.1 million and $0.1 million accrued for interest and penalties on unrecognized tax benefits, respectively.
At October 31, 2017, we had $4.9 million of unrecognized tax benefits for uncertain tax positions and $0.1 million of related accrued interest and penalties. We are unable to reasonably estimate the amount and period in which these liabilities might be paid.
We do not provide for U.S. Federal income taxes on undistributed earnings of consolidated foreign subsidiaries, as such earnings are intended to be indefinitely reinvested in those operations. Determination of the potential deferred income tax liability on these undistributed earnings is not practicable because such liability, if any, is dependent on circumstances that exist if and when remittance occurs. The circumstances that would affect the calculations would be the source location and amount of the distribution, the underlying tax rate already paid on the earnings, foreign withholding taxes and the opportunity to use foreign tax credits.
14. Segment information
Our business is strategically aligned into three segments: Medical Imaging, Ultrasound, and Security and Detection. Our business segments are described as follows:
|
•
|
Medical Imaging
primarily includes systems and subsystems for CT and MRI medical imaging equipment as well as state-of-the-art, selenium-based detectors for screening of breast cancer and other diagnostic applications in mammography.
|
|
•
|
Ultrasound
includes ultrasound systems and transducers primarily in the urology, surgery, and Anesthesia markets.
|
|
•
|
Security and Detection
includes advanced threat detecting CT systems utilizing our expertise in advanced imaging technology, primarily used in the checked baggage screening at airports worldwide.
|
17
The tables below present information about our reportable segments:
|
|
Three Months Ended
|
|
|
|
October 31,
|
|
(in millions)
|
|
2017
|
|
|
2016
|
|
Product revenue:
|
|
|
|
|
|
|
|
|
Medical Imaging
|
|
$
|
52.0
|
|
|
$
|
66.5
|
|
Ultrasound
|
|
|
37.4
|
|
|
|
35.6
|
|
Security and Detection
|
|
|
16.4
|
|
|
|
18.1
|
|
Total product revenue
|
|
$
|
105.8
|
|
|
$
|
120.2
|
|
Engineering revenue:
|
|
|
|
|
|
|
|
|
Medical Imaging
|
|
$
|
1.1
|
|
|
$
|
0.7
|
|
Ultrasound
|
|
|
-
|
|
|
|
0.2
|
|
Security and Detection
|
|
|
-
|
|
|
|
-
|
|
Total engineering revenue
|
|
$
|
1.1
|
|
|
$
|
0.9
|
|
Net revenue:
|
|
|
|
|
|
|
|
|
Medical Imaging
|
|
$
|
53.1
|
|
|
$
|
67.2
|
|
Ultrasound
|
|
|
37.4
|
|
|
|
35.8
|
|
Security and Detection
|
|
|
16.4
|
|
|
|
18.1
|
|
Total net revenue
|
|
$
|
106.9
|
|
|
$
|
121.1
|
|
Income (loss) from operations:
|
|
|
|
|
|
|
|
|
Medical Imaging (A)
|
|
$
|
4.8
|
|
|
$
|
6.7
|
|
Ultrasound (B)
|
|
|
1.3
|
|
|
|
(5.8
|
)
|
Security and Detection
|
|
|
1.8
|
|
|
|
3.0
|
|
Total income from operations
|
|
|
7.9
|
|
|
|
3.9
|
|
Total other income (loss), net
|
|
|
0.2
|
|
|
|
(0.4
|
)
|
Income before income taxes
|
|
$
|
8.1
|
|
|
$
|
3.5
|
|
|
|
As of
|
|
|
As of
|
|
|
|
October 31,
|
|
|
July 31,
|
|
(in millions)
|
|
2017
|
|
|
2017
|
|
Identifiable total assets by segment:
|
|
|
|
|
|
|
|
|
Medical Imaging
|
|
$
|
159.6
|
|
|
$
|
169.1
|
|
Ultrasound
|
|
|
132.7
|
|
|
|
133.6
|
|
Security and Detection
|
|
|
39.7
|
|
|
|
36.0
|
|
Total reportable segment assets
|
|
|
332.0
|
|
|
|
338.7
|
|
Corporate assets (C)
|
|
|
203.0
|
|
|
|
197.0
|
|
Total identifiable assets
|
|
$
|
535.0
|
|
|
$
|
535.7
|
|
(A)
|
Includes restructuring charges of $0.1 million and $0.02 million for the three months ended October 31, 2017 and 2016, respectively.
|
(B)
|
Includes restructuring charges of $0.4 million and $0.01 million for the three months ended October 31, 2017 and 2016, respectively.
|
(C)
|
Includes cash and cash equivalents of $132.6 million and $135.2 million as of October 31, 2017 and July 31, 2017, respectively.
|
15. Guarantees, commitments and contingencies
Guarantees and Indemnification Obligations
Our standard OEM and supply agreements entered into in the ordinary course of business typically contain an indemnification provision pursuant to which we indemnify, hold harmless, and agree to reimburse the indemnified party for losses suffered or incurred by the indemnified party in connection with any U.S. patent or any copyright or other intellectual property infringement claim by any third party with respect to our products. Such provisions generally survive termination or expiration of the agreements. The potential amount of future payments we could be required to make under these indemnification provisions is, in some instances, unlimited. Our costs to defend lawsuits or settle claims related to these indemnification agreements have been insignificant to date. As a result, we believe that our estimated exposure on these agreements is currently minimal. Accordingly, we have no liabilities recorded for these agreements as of October 31, 2017.
18
Generally, we warrant that our products will perform in all m
aterial respects in accordance with our standard published specifications in effect at the time of delivery of the products to the customer for a period ranging from 12 to 60 months from the date of delivery. We provide for the estimated cost of product an
d service warranties based on specific warranty claims, claim history, and engineering estimates, where applicable.
The following table presents our product warranty liability as of October 31, 2017:
|
|
As of
|
|
|
|
October 31,
|
|
(in millions)
|
|
2017
|
|
Beginning balance
|
|
$
|
5.3
|
|
Provision
|
|
|
0.9
|
|
Warranty activity during the period
|
|
|
(1.3
|
)
|
Ending balance
|
|
$
|
4.9
|
|
At October 31, 2017 and July 31, 2017, we had deferred revenue for extended product warranty contracts of $0.4 million and $0.4 million, respectively.
Revolving Credit Agreements
On November 23, 2015, we entered into a five-year revolving credit agreement, or Credit Agreement, with the financial institutions identified therein as lenders, which included JPMorgan Chase Bank, N.A., TD Bank, N.A., Wells Fargo Bank, N.A., HSBC Bank, N.A., and People’s United Bank, N.A. Effective August 25, 2017, HSBC exited the Credit Agreement, and was replaced with Citibank. The Credit Agreement provides $100.0 million in available credit and expires on November 23, 2020, when all outstanding borrowings must be paid in full. The credit facility does not require amortization of principal and may be reduced before maturity in whole or in part at our option without penalty. Upon entry into the Credit Agreement, we terminated without penalty a $100.0 million five-year, revolving credit agreement entered into on October 11, 2011 and previously paid in full in accordance with its terms. Borrowings under the Credit Agreement may be used for general corporate purposes, including permitted acquisitions. The amount of available credit can be increased under specified circumstances up to $200.0 million in aggregate. We are the sole borrower under the Credit Agreement. The obligations under the credit facility are guaranteed as required to be by our material domestic subsidiaries as designated by us from time to time or as required under the Credit Agreement. There are no pledges of the capital stock or assets of our international subsidiaries.
Interest rates on borrowings outstanding under the credit facility range from 1.25% to 1.75% above the LIBOR rate, or, at our option range from 0.00% to 1.00% above a defined base rate, the amount in each case varying based upon our leverage ratio. A quarterly commitment fee ranging from 0.20% to 0.35% per annum is applicable on the undrawn portion of the credit facility, based upon our leverage ratio.
The Credit Agreement limits our and our subsidiaries’ ability to, among other things: incur additional indebtedness; incur liens or guarantee obligations; pay dividends or make other distributions; make investments; dispose of assets; and engage in transactions with affiliates except on an arms-length basis. In addition, the Credit Agreement requires us to maintain the following financial ratios:
|
•
|
A leverage ratio, defined as consolidated funded indebtedness to consolidated trailing four quarters earnings before interest, taxes, depreciation and amortization, or EBITDA, with the adjustments as stipulated in the Credit Agreement, of no greater than 2.75:1.00 (with a temporary step-up in the event of certain acquisitions); and
|
|
•
|
An interest coverage ratio, defined as the ratio of consolidated trailing four quarters adjusted EBITDA to consolidated interest charges of no less than 3.00:1.00 at any time.
|
As of October 31, 2017, our leverage ratio was 0.004:1.00 and our interest coverage ratio was not applicable as we had no attributable interest expense. As of October 31, 2017, we were in full compliance with all financial and operating covenants contained in the Credit Agreement.
Any failure to comply with the financial or operating covenants of the credit facility would prevent us from being able to borrow and would also constitute a default, permitting the lenders to, among other things, accelerate repayment of outstanding borrowings, including all accrued interest and fees, and to terminate the credit facility. A change in control, as defined in the Credit Agreement, would also constitute an event of default, permitting the lenders to accelerate repayment and terminate the Credit Agreement.
In connection with entering into the Credit Agreement, we incurred approximately $0.5 million of transaction costs, which are being amortized over the five-year life of the credit facility.
19
As of October 31, 2017 and July 31, 2017, we had approximately $1.2 million in other revolving credit facilities with banks available for direct borrowings.
We did not have any borrowing outstanding under any of our credit facilities at October 31, 2017 and July 31, 2017, respectively.
Legal Claims
We are subject to litigation, claims, investigations and audits arising from time to time in the ordinary course of our business. Although legal proceedings are inherently unpredictable, we believe that we have valid defenses with respect to those matters currently pending against us and intend to defend ourselves vigorously. The outcome of these matters, individually and in the aggregate, is not expected to have a material impact on our cash flows, results of operations, or financial position. We record losses when estimable and probable in accordance with U.S. GAAP.
On July 31, 2017, twenty-four former interest-holders of Oncura Partners Diagnostics, LLC (“Plaintiffs”) filed suit in the District Court of Travis County, Texas against Analogic Corporation (“Analogic”) and Oncura Partners Diagnostics, LLC (“Oncura”) (together “Defendants”) alleging claims arising out of Analogic’s acquisition of Oncura from Plaintiffs in 2016. Plaintiffs asserted claims for breach of contract, anticipatory repudiation, fraud, negligent misrepresentation, breach of implied duty of good faith and fair dealing, unjust enrichment, and declaratory judgement; they seek unspecified damages in excess of $1.0 million. On August 25, 2017, Defendants timely removed the action to federal court in Texas and the case was subsequently transferred to the United States District Court for the Southern District of New York. On September 29, 2017, Plaintiffs filed an Amended Complaint, setting forth the same claims and seeking the same damages set forth in their original pleading. We believe that the claims asserted by Plaintiffs are without merit and intend to defend the matter vigorously. We cannot reasonably estimate any loss or range of such loss that may arise from this matter at this time.
16. Subsequent events
We declared a dividend of $0.10 per share of common stock on December 1, 2017, which will be paid on December 29, 2017 to stockholders of record on December 15, 2017.
20